Summary:
HYDERABAD, India and BOSTON, Mass., April 19, 2022 /PRNewswire/ -- Excelra, a leading global Data and Analytics provider for Life Science organizations, has announced a strategic majority investment in Anlitiks, a young and rapidly growing technology company in the value and evidence domain.
The investment reinforces Excelra"s push into the Health Economics and Outcomes Research (HEOR) and Real-World Evidence (RWE) analytics area.
This deal is a testimony to Excelra"s commitment to drug discovery and commercialization by combining deep scientific domain expertize with cutting-edge technology and analytics solutions.
Anlitiks, headquartered in Boston, is a HEOR and RWE company, founded by Kannan Rajagopalan, a technology entrepreneur.
According to Kannan, Anlitiks" mission is to help Life Sciences organizations translate real-world data rapidly into value evidence, using a unique data + platform + service approach.
The engine driving the business is Anlitiks" RapidAnalyzer™, a flexible, data-agnostic platform that captures the entire lifecycle of HEOR/RWE from hypothesis, data integration, analysis, visualization to a research report.